ABVC BioPharma 2024 Q4 Earnings Strong Turnaround as Net Income Surges 118.4%

ABVC BioPharma (ABVC) reported its fiscal 2024 Q4 earnings on August 13, 2025. The company delivered a significant earnings turnaround despite a revenue decline, marking a notable shift in its financial trajectory.

ABVC BioPharma reported a total revenue of $1,966 for fiscal 2024 Q4, reflecting a 9.2% decline compared to $2,165 in the same period of 2023. The drop in revenue underscored ongoing market challenges but did not prevent the company from achieving profitability.

Revenue

Earnings/Net Income
ABVC BioPharma recorded a net income of $128,943 in 2024 Q4, compared to a net loss of $700,309 in 2023 Q4, representing a 118.4% improvement. On an earnings per share (EPS) basis, the company posted a profit of $0.02 per share, reversing a $0.05 loss per share from the previous year. This marked a 134.2% positive change and highlighted a strong earnings turnaround. Despite this, the company had sustained losses over the prior six years during the same quarter, indicating long-standing financial challenges.

Price Action

Post Earnings Price Action Review
The stock experienced mixed price action following the earnings report. While the stock edged up 0.68% during the latest trading day and climbed 3.85% over the most recent full trading week, it plummeted 15.38% month-to-date. The post-earnings strategy of buying shares on the report date and holding for 30 days underperformed significantly, returning -47.07% compared to a 46.32% return for the benchmark. This resulted in an excess return of -93.39% and a CAGR of -19.72% over the three-year period. The strategy also faced high volatility of 177.48% and a maximum drawdown of 0.00%, reinforcing its risk profile.

CEO Commentary
Uttam Yashwant Patil, Ph.D., Chief Executive Officer of ABVC BioPharma, reiterated the company’s commitment to developing safe and all-natural therapeutics. He emphasized partnerships with prestigious research institutions to advance the company’s pipeline of plant-based drugs for challenging diseases, including depression, ADHD, and oncology. Patil expressed optimism about the growing pipeline and the company’s readiness to advance several drug candidates into phase III clinical trials within the next five years. These trials are currently underway in Thailand, Australia, Taiwan, and Stanford University, reflecting a broad and strategic approach to commercialization.

Guidance
ABVC BioPharma did not provide specific quantitative guidance for 2024 Q4 but indicated its readiness to advance multiple drug candidates into phase III trials over the next five years. The company remains focused on plant-based medicine and the long-term commercialization of its portfolio, expressing confidence in the future growth and profitability of its therapeutic offerings.

Additional News
In Nigeria, the Federal Government announced plans to unlock $150 billion in dormant land capital to boost economic growth, while Lagos State introduced a new tenancy bill to cap estate agent fees at 5%. Elsewhere, Nigeria approved a $346 million foreign military sale with the U.S. and plans to temporarily close its border with Niger Republic during a by-election in Jigawa State. In global markets, Bitcoin hit a record high of over $124,000 amid favorable legislation and rising equity markets.